1387637-34-4

Basic information

• Product Name: 4-((2,4-dichlorobenzyl)oxy)-2-hydroxybenzaldehyde
• Synonyms: 4-((2,4-dichlorobenzyl)oxy)-2-hydroxybenzaldehyde
• CAS NO: 1387637-34-4
• Molecular Weight: 297.138
• Mol File: 1387637-34-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-((2,4-dichlorobenzyl)oxy)-2-hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((2,4-dichlorobenzyl)oxy)-2-hydroxybenzaldehyde(1387637-34-4)
• EPA Substance Registry System: 4-((2,4-dichlorobenzyl)oxy)-2-hydroxybenzaldehyde(1387637-34-4)

Safety Data

• Hazardous Substances Data: 1387637-34-4(Hazardous Substances Data)

Upstream product

• 94-99-5 2,4-Dichlorobenzyl chloride 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 1388265-84-6 C₃₇H₃₄Cl₂FN₇O₄S 

Relevant articles and documents

Synthesis and biological evaluation of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone moiety as potent antitumor agents

A novel series of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone moiety were designed, synthesized, and evaluated for their procaspase-3 kinase activation activities and antiproliferative activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN-45, and MDA-MB-231). Most target compounds showed moderate to excellent cytotoxic activity against all five tested cancer lines. The most promising compound 18e (procaspase-3 EC50- 0.31μM) with IC50 values ranging from 0.24 to 0.92 μM against all tested cell lines was 4.24-12.2 times more active than PAC-1 (procaspase-3 EC50 - 0.41 μM). Structure-activity relationship studies indicated that the phenyl group on the 2-hydroxyphenyl ring (moiety A) was critical for pharmacological activity in vitro. In addition, introduction of a benzyloxyl group on moiety A and a mono-electron-withdrawing group at the 4-position of the benzyloxyl group were more favorable for antitumor activity. Moreover, reduction of the electron density in the phenyl ring of the benzyloxy group led to a dramatic decrease in the procaspase-3 kinase activation activity. -

Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents

A series of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety were designed and synthesized and their cytotoxic activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN45, and MDA-MB-231) were screened in vitro. Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 15g (procaspase-3 EC50 = 1.42 μM) and 16b (procaspase-3 EC 50 = 0.25 μM) exhibited excellent antitumor activity with IC 50 values ranging from 0.14 μM to 0.98 μM against all cancer cell lines, which were 1.8-8.7 times more active than the first procaspase activating compound (PAC-1) (procaspase-3 EC50 = 4.08 μM). The structure-activity relationship (SAR) analyses indicated that the introduction of a lipophilic group (a benzyloxy or heteroaryloxy group) at the 4-position of the 2-hydroxy phenyl ring was beneficial to antitumor activity, and the presence of substituents containing nitrogen that are positively charged at physiological pH could also improve antitumor activity. It was also confirmed that the steric effect of the 4-position substituent of the benzyloxy group had a significant influence on cytotoxic activity.